Eddie Pan

Eddie Pan

Expertise: Institutional Investments, Insider Activity, Disruptive Innovations

Education: BBA, Finance, James Madison University

About Eddie:
Eddie Pan specializes in institutional investments and insider activity. He has been enamored with hedge funds since he began investing and regularly collaborates with industry executives to craft editorial pieces. Tracking the investments of institutional investors and insiders can provide a vast array of knowledge that is scarcely covered.

After receiving his BBA in Finance from James Madison University, Eddie began his career at Accenture as an analyst. Today, he writes for InvestorPlace’s Today’s Market team, which centers on the latest news involving popular stocks.

Eddie got his start in the financial media world by publishing articles on top-performing hedge funds and their investment strategies on Substack. He still publishes pieces on his Substack today.

Common Stocks and Uncommon Profits by Philip A. Fisher is Eddie’s favorite investment book. Fisher’s 15 Points have heavily influenced his investment strategy.

Recent Articles

Embraer SPAC Merger: 7 Things to Know About the Deal Bringing eVTOL Unit Eve Public

Shares of ERJ stock are trading higher today after breaking news of a merger. Here's what to know about the Embraer SPAC merger.

BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.

PLTR Stock Alert: 5 Things to Know About Palantir’s Latest Partnership

Today, Palantir announced a multi-year partnership with Dewpoint Therapeutics, exciting PLTR stock investors. Here's what to know.

RIVN, LCID, GOEV, FSR: Why Are EV Stocks Down Today?

After a high-flying 2021, EV stocks are taking a breather as investors adjust their expectations for 2022.

LCID Stock Price Predictions: Why One Analyst Sees Lucid Motors Stalling Out

Guggenheim's Ali Faghri initiated coverage on LCID stock with a neutral rating and a $38 price target. Here's what other analysts think.